Medical imaging technology company Adaptix Limited (Adaptix) has submitted a 510(k) application to the U.S. Food and Drug Administration for its first medical imaging product (“NeXt 3D-Ortho”), allowing the company to begin marketing its Point-of-Care 3D orthopedic system in the United States.
Adaptix, based at Oxford University Science Park, has developed novel technologies that allow affordable, low-dose 3D imaging at the Point-of-Care using Digital Tomosynthesis (DT), to provider quicker, more accurate diagnosis possibilities.
Also Read: Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer’s Disease
2D X-ray is currently the world’s dominant diagnostic modality, but frequently results in inconclusive reads due to areas of clinical interest being obscured by overlying and underlying tissues. This leads to diagnostic “misses” and delays, additional referrals for an “over-read,” and excessive and expensive escalation to Computer Tomography (CT) or MRI, as well as potentially the unnecessary immobilisation of a limb for a patient waiting diagnosis.
CT provides a more sensitive 3D image but at a far greater cost in terms of money, time and radiation dosage to the patient. Access to CT is also more limited particularly in some countries or regions, resulting in delayed diagnosis and extended travel by the patient.
Mark Evans, Adaptix‘s CEO, stated, “This is the first of many innovations that Adaptix is excited about bringing to medical markets. The U.K. is the country that invented the first clinical CT and MRI scanners, and our new low-cost 3D imaging technology builds on the long-standing U.K. pedigree of innovation in medical imaging. We hope that our patent-protected technology will become even more widely deployed and that one day Adaptix’s technologies will touch the lives of everyone through medical and dental applications.”
There is a drive within healthcare systems towards a new diagnostics model where more facilities will be made available in free standing locations away from main hospital sites, to Regional Diagnostic Centres and even commercial and retail locations. This will support earlier diagnosis, greater convenience to patients and the drive to reduce health inequalities. Adaptix’s low-cost deployable 3D imaging will help change the location of service delivery within and beyond the hospital environment, and meet diagnostic needs faster and at a lower cost